Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy

Jishnu Malgie*, Pascal R.D. Clephas, Hans Peter Brunner-La Rocca, Rudolf A. de Boer, Jasper J. Brugts*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

10 Citations (Scopus)
25 Downloads (Pure)

Abstract

Multiple landmark trials have helped to advance the treatment of heart failure with reduced ejection fraction (HFrEF) significantly over the past decade. These trials have led to the introduction of four main drug classes into the 2021 ESC guideline, namely angiotensin-receptor neprilysin inhibitors/angiotensin-converting-enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. The life-saving effect of these therapies has been shown to be additive and becomes apparent within weeks, which is why maximally tolerated or target doses of all drug classes should be strived for as quickly as possible. Recent evidence, such as the STRONG-HF trial, demonstrated that rapid drug implementation and up-titration is superior to the traditional and more gradual step-by-step approach where valuable time is lost to up-titration. Accordingly, multiple rapid drug implementation and sequencing strategies have been proposed to significantly reduce the time needed for the titration process. Such strategies are urgently needed since previous large-scale registries have shown that guideline-directed medical therapy (GDMT) implementation is a challenge. This challenge is reflected by generally low adherence rates, which can be attributed to factors considering the patient, health care system, and local hospital/health care provider. This review of the four medication classes used to treat HFrEF seeks to present a thorough overview of the data supporting current GDMT, discuss the obstacles to GDMT implementation and up-titration, and identify multiple sequencing strategies that could improve GDMT adherence. Graphical Abstract: Sequencing strategies for GDMT implementation. GDMT: guideline-directed medical therapy; ACEi: angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; ARNi: angiotensin receptor–neprilysin inhibitor; BB: beta-blocker; MRA: mineralocorticoid receptor antagonist; SGLT2i: sodium–glucose co-transporter 2 inhibitor[Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)1221-1234
Number of pages14
JournalHeart Failure Reviews
Volume28
Issue number5
Early online date14 Jun 2023
DOIs
Publication statusPublished - Sept 2023

Bibliographical note

Publisher Copyright: © 2023, The Author(s).

Fingerprint

Dive into the research topics of 'Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy'. Together they form a unique fingerprint.

Cite this